Physicians embrace AI scribe technology, reporting enhanced efficiency, reduced burnout, and improved documentation quality in clinical workflows.

The BeeLine trial is a placebo-controlled study designed to evaluate radiprodil’s impact on both seizure frequency and non-seizure symptoms associated with GRIN-NDD.

Training tools and EHR prompts boosted pediatricians’ adherence to early peanut introduction guidelines in a new trial.

Peace Madueme, MD, explains how Florida’s pre-sports cardiac evaluations—and upcoming ECG mandate—strengthen youth safety in athletics.

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children 2 to 5 years.

Try to diagnose this patient with 3 days of right-sided neck swelling.

Lori Handy, MD, MSCE, addresses rising vaccine inquiries, emphasizing informed decisions that balance risks and benefits for children's health and safety.

The once-daily, steroid-free cream can be used anywhere on the body for treatment, and for any duration, according to Arcutis.

Combination vaccines enhance childhood immunization by reducing the number of shots, improving adherence, and potentially increasing overall vaccination rates.

Watch our FDA pipeline news recap for the month of September 2025, as well as a preview of a key PDUFA date in October.

Ellen Fremion, MD, outlines strategies to support smooth transitions from pediatric to adult care, stressing early planning and strong collaboration.

Ingrid Polcari, MD, highlights concerns with teen skin care trends and emphasizes simple, age-appropriate routines tailored to patient needs.

View our Q3 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Ingrid Polcari, MD, discusses acne severity, treatment options, and the importance of persistence and open discussion in pediatric care.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from September 2025.

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

Decline in maternal smoking linked to fewer US newborns with gastroschisis, highlighting benefits of public health efforts.

Unintentional marijuana ingestions in children under 5 rose over 1,000% in 7 years, with edibles and pandemic-related factors fueling the trend.

Over half of youth firearm suicides involved a parent’s gun, with most stored unlocked and loaded, underscoring the need for secure storage.

Mothers with multiple adverse childhood experiences faced double the risk of preterm birth, highlighting intergenerational health effects.

Youth suicides by sodium nitrite/nitrate are rising, highlighting prevention gaps and opportunities for early medical and public health intervention.

Federal backup camera mandate cut pediatric backover injuries and deaths, though risks remain for children in older vehicles without cameras.

Nearly 1 in 4 children with firearm injuries had prior ED visits for crashes or violence, highlighting opportunities for early intervention.

FDA approves guselkumab as the first IL-23 inhibitor for children 6 years and older with plaque psoriasis or psoriatic arthritis.